Welcome to our dedicated page for Protara Therapeutics SEC filings (Ticker: TARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Protara Therapeutics, Inc. (TARA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Protara is a clinical-stage biotechnology company listed on The Nasdaq Global Market under the symbol TARA, and its filings offer insight into the development of its investigational therapies TARA-002 and IV Choline Chloride, as well as its capital raising activities.
Among the key documents available are Form 8-K current reports, where Protara reports material events such as public offerings of common stock under its shelf registration statement on Form S-3, interim clinical data from the Phase 2 ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC), and interim results from the Phase 2 STARBORN-1 trial in pediatric lymphatic malformations (LMs). These filings also describe regulatory feedback from the U.S. Food and Drug Administration (FDA) on registrational trial designs and summarize safety and efficacy data disclosed in associated press releases and investor presentations.
Investors can also use this page to track financing-related disclosures, including details of underwritten public offerings, the number of shares issued, gross proceeds, and the intended use of net proceeds, which Protara states include funding the clinical development of TARA-002 and other clinical programs, as well as working capital and general corporate purposes.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points from lengthy documents, helping readers quickly understand the implications of clinical updates, regulatory interactions, and financing transactions. Real-time updates from EDGAR mean that new Protara filings, such as additional 8-Ks, quarterly or annual reports when filed, and other registration statements, can be reviewed soon after submission.
For users interested in governance and ownership details, this page also serves as a starting point to locate information typically found in periodic and transactional filings, while AI-generated overviews can make complex regulatory language more accessible to a broader audience.
Protara Therapeutics Schedule 13G: Millennium group reports shared ownership of 2,759,231 common shares (5.1%). The filing states that Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander share voting and dispositive power over 2,759,231 shares of Protara Therapeutics common stock as of 02/25/2026. A Joint Filing Agreement dated 02/27/2026 is attached, and signatures by representatives, including Israel A. Englander, are included.
667, L.P. reported the sale of 26,755 shares of Common Stock. The Form 144 excerpt lists a sale date of 02/24/2026 and a reported value of $161,584.00.
The filing names Canaccord Genuity LLC as a broker and includes additional trade dates of 12/08/2025 and 02/25/2026 in the securities table.
TARA: A Form 144 filing reports planned or completed dispositions of Common Stock by selling holders. The filing shows a sale of 322,039 shares by Baker Brothers Life Sciences, L.P. on 02/24/2026. It also lists proposed methods and additional sale quantities including 24,186 shares (underwriter) dated 12/08/2025 and 923,293 shares (broker) dated 02/25/2026.
The filing lists intermediaries such as Canaccord Genuity LLC and identifies NASDAQ as the exchange. These entries indicate registered resale activity by institutional holders rather than corporate actions by the issuer.
Protara Therapeutics filed an 8-K highlighting updated interim Phase 2 ADVANCED-2 data for its investigational cell-based therapy TARA-002 in high-risk non-muscle invasive bladder cancer. In the BCG-unresponsive cohort, TARA-002 achieved a high-grade complete response rate of 65.7% (23/35) at any time, 68.2% at six months and 33.3% at 12 months. In BCG-naïve patients, the high-grade complete response rate was 72.4% (21/29) at any time, 66.7% at six months and 57.9% at 12 months. Across 74 treated patients, most treatment-related adverse events were Grade 1 and transient, with no Grade 3 or higher treatment-related events, no related serious events and no discontinuations due to toxicity. Protara plans to complete enrollment of the registrational BCG-unresponsive cohort of ADVANCED-2 and to initiate the registrational ADVANCED-3 trial in BCG-naïve patients in the second half of 2026, while also advancing TARA-002 in pediatric lymphatic malformations and IV choline chloride for parenteral nutrition–dependent patients.
Janus Henderson Group plc reported beneficial ownership of 5,141,616 shares of Protara Therapeutics, Inc. common stock, representing 10.0% of the class as of 12/31/2025. All shares are held with shared voting and dispositive power.
The stake is attributed to multiple Janus Henderson asset management subsidiaries that exercise investment and voting discretion for their managed portfolios, which receive all dividends and sale proceeds. Janus Henderson certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Protara Therapeutics.
Protara Therapeutics, Inc. filed a prospectus supplement updating its existing resale registration covering up to 21,686,760 shares of common stock. These shares include currently held common stock as well as shares issuable upon exercise of pre-funded warrants and common warrants held by selling stockholders.
The update adds Funicular Funds, LP as a selling stockholder following an assignment on January 28, 2026 by OTA Trading Fund 1 LLC of common warrants exercisable for up to 142,400 common stock warrant shares. Funicular Funds, LP does not own common stock as of January 30, 2026 and is subject to a 4.99% beneficial ownership limitation after warrant exercises.
Protara Therapeutics VP, Controller Hannah Fry reported a tax-related share withholding. On 01/26/2026, 1,457 shares of Protara Therapeutics common stock were withheld by the company at a price of $6.67 per share to cover income tax obligations tied to the vesting of a restricted stock unit award originally granted on January 24, 2025. After this withholding, Fry beneficially owned 42,723 shares of Protara common stock in direct ownership.
Protara Therapeutics, Inc. Chief Financial Officer Patrick Fabbio reported an automatic share withholding related to equity compensation. On 01/26/2026, 3,261 shares of common stock were withheld by the company at a price of $6.67 per share to cover income tax obligations arising from the vesting of a previously granted restricted stock unit award. After this tax withholding, Fabbio directly beneficially owns 64,115 shares of Protara common stock.